US Bancorp DE Buys 601 Shares of Twist Bioscience Co. (NASDAQ:TWST)

US Bancorp DE lifted its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 72.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,436 shares of the company’s stock after buying an additional 601 shares during the quarter. US Bancorp DE’s holdings in Twist Bioscience were worth $67,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after buying an additional 82,953 shares during the period. Victory Capital Management Inc. lifted its position in shares of Twist Bioscience by 7.7% during the 3rd quarter. Victory Capital Management Inc. now owns 331,809 shares of the company’s stock valued at $14,991,000 after acquiring an additional 23,638 shares during the period. Chesapeake Capital Corp IL boosted its stake in Twist Bioscience by 27.9% during the third quarter. Chesapeake Capital Corp IL now owns 6,176 shares of the company’s stock worth $287,000 after acquiring an additional 1,347 shares in the last quarter. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the third quarter worth $43,992,000. Finally, Jennison Associates LLC increased its stake in Twist Bioscience by 29.6% in the third quarter. Jennison Associates LLC now owns 377,894 shares of the company’s stock valued at $17,073,000 after purchasing an additional 86,399 shares in the last quarter.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,654 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $44.90, for a total value of $74,264.60. Following the completion of the sale, the chief executive officer now owns 673,064 shares of the company’s stock, valued at approximately $30,220,573.60. This trade represents a 0.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,712 shares of company stock worth $1,597,720 in the last ninety days. 3.01% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TWST. Barclays set a $58.00 target price on Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Finally, Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Trading Up 6.0 %

Shares of TWST stock opened at $42.34 on Tuesday. The stock has a market capitalization of $2.53 billion, a PE ratio of -12.53 and a beta of 2.15. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The business has a 50-day moving average of $45.64 and a 200 day moving average of $45.27. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.75) EPS. As a group, sell-side analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.